Literature DB >> 24151226

Piperlongumine inhibits NF-κB activity and attenuates aggressive growth characteristics of prostate cancer cells.

Serge Ginzburg1, Konstantin V Golovine, Petr B Makhov, Robert G Uzzo, Alexander Kutikov, Vladimir M Kolenko.   

Abstract

BACKGROUND: Elevated NF-κB activity has been previously demonstrated in prostate cancer cell lines as hormone-independent or metastatic characteristics develop. We look at the effects of piperlongumine (PL), a biologically active alkaloid/amide present in piper longum plant, on the NF-κB pathway in androgen-independent prostate cancer cells.
METHODS: NF-κB activity was evaluated using Luciferase reporter assays and Western blot analysis of p50 and p65 nuclear translocation. IL-6, IL-8, and MMP-9 levels were assessed using ELISA. Cellular adhesion and invasiveness properties of prostate cancer cells treated with PL were also assessed.
RESULTS: NF-κB DNA-binding activity was directly down-regulated with increasing concentrations of PL, along with decreased nuclear translocation of p50 and p65 subunits. Expression of IL-6, IL-8, MMP-9, and ICAM-1 was attenuated, and a decrease of cell-to-matrix adhesion and invasiveness properties of prostate cancer cells were observed.
CONCLUSIONS: PL-mediated inhibition of NF-κB activity decreases aggressive growth characteristics of prostate cancer cells in vitro.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  IL-6; IL-8; MMP-9; NF-κB; ROS; adhesion; apoptosis; cytokines; piperlongumine; prostate cancer

Mesh:

Substances:

Year:  2013        PMID: 24151226      PMCID: PMC4052841          DOI: 10.1002/pros.22739

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  55 in total

Review 1.  Tumor metastasis: mechanistic insights and clinical challenges.

Authors:  Patricia S Steeg
Journal:  Nat Med       Date:  2006-08       Impact factor: 53.440

2.  Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells.

Authors:  Viktor Grünwald; Linda DeGraffenried; Douglas Russel; William E Friedrichs; Ratna B Ray; Manuel Hidalgo
Journal:  Cancer Res       Date:  2002-11-01       Impact factor: 12.701

3.  The changing landscape in the treatment of metastatic castration-resistant prostate cancer.

Authors:  Joelle El-Amm; Jeanny B Aragon-Ching
Journal:  Ther Adv Med Oncol       Date:  2013-01       Impact factor: 8.168

4.  Transcriptional regulation of intercellular adhesion molecule 1 by phorbol ester in human neuroblastoma cell line SK-N-SH involves jun- and fos-containing activator protein 1 site binding complex(es).

Authors:  A R Farina; L Cappabianca; A R Mackay; A Tiberio; A Tacconelli; A Tessitore; L Frati; S Martinotti; A Gulino
Journal:  Cell Growth Differ       Date:  1997-07

5.  Identification and characterization of an IkappaB kinase.

Authors:  C H Régnier; H Y Song; X Gao; D V Goeddel; Z Cao; M Rothe
Journal:  Cell       Date:  1997-07-25       Impact factor: 41.582

6.  MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1.

Authors:  N L Malinin; M P Boldin; A V Kovalenko; D Wallach
Journal:  Nature       Date:  1997-02-06       Impact factor: 49.962

7.  The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation.

Authors:  H Hsu; J Xiong; D V Goeddel
Journal:  Cell       Date:  1995-05-19       Impact factor: 41.582

8.  Gene expression of angiogenic factors correlates with metastatic potential of prostate cancer cells.

Authors:  Ravikumar Aalinkeel; Madhavan P N Nair; Gerald Sufrin; Supriya D Mahajan; Kailash C Chadha; Ram P Chawda; Stanley A Schwartz
Journal:  Cancer Res       Date:  2004-08-01       Impact factor: 12.701

9.  Akt is a downstream target of NF-kappa B.

Authors:  Fanyin Meng; Li Liu; Paul C Chin; Santosh R D'Mello
Journal:  J Biol Chem       Date:  2002-06-06       Impact factor: 5.157

10.  Association between tumor necrosis factor in serum and cachexia in patients with prostate cancer.

Authors:  J Nakashima; M Tachibana; M Ueno; A Miyajima; S Baba; M Murai
Journal:  Clin Cancer Res       Date:  1998-07       Impact factor: 12.531

View more
  32 in total

1.  S100A16 promotes cell proliferation and metastasis via AKT and ERK cell signaling pathways in human prostate cancer.

Authors:  Weidong Zhu; Yi Xue; Chao Liang; Rihua Zhang; Zhihong Zhang; Hongyan Li; Dongming Su; Xiubin Liang; Yuanyuan Zhang; Qiong Huang; Menglan Liu; Lu Li; Dong Li; Allan Z Zhao; Yun Liu
Journal:  Tumour Biol       Date:  2016-05-30

2.  Structural and Biochemical Analyses Reveal the Mechanism of Glutathione S-Transferase Pi 1 Inhibition by the Anti-cancer Compound Piperlongumine.

Authors:  Wayne Harshbarger; Sudershan Gondi; Scott B Ficarro; John Hunter; Durga Udayakumar; Deepak Gurbani; William D Singer; Yan Liu; Lianbo Li; Jarrod A Marto; Kenneth D Westover
Journal:  J Biol Chem       Date:  2016-11-21       Impact factor: 5.157

3.  Piperlongumine targets NF-κB and its downstream signaling pathways to suppress tumor growth and metastatic potential in experimental colon cancer.

Authors:  Sandeep Kumar; Navneet Agnihotri
Journal:  Mol Cell Biochem       Date:  2021-01-12       Impact factor: 3.396

4.  Piperlongumine and its analogs down-regulate expression of c-Met in renal cell carcinoma.

Authors:  Konstantin Golovine; Peter Makhov; Sei Naito; Henish Raiyani; Jeffrey Tomaszewski; Reza Mehrazin; Alexei Tulin; Alexander Kutikov; Robert G Uzzo; Vladimir M Kolenko
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

5.  Piperlongumine induces apoptotic and autophagic death of the primary myeloid leukemia cells from patients via activation of ROS-p38/JNK pathways.

Authors:  Xin-xin Xiong; Ju-mei Liu; Xin-yao Qiu; Feng Pan; Shang-bin Yu; Xiao-qian Chen
Journal:  Acta Pharmacol Sin       Date:  2015-01-26       Impact factor: 6.150

6.  Modulation of TLR/NF-κB/NLRP Signaling by Bioactive Phytocompounds: A Promising Strategy to Augment Cancer Chemotherapy and Immunotherapy.

Authors:  Sajad Fakhri; Seyed Zachariah Moradi; Akram Yarmohammadi; Fatemeh Narimani; Carly E Wallace; Anupam Bishayee
Journal:  Front Oncol       Date:  2022-03-01       Impact factor: 6.244

7.  Transcriptome Analysis of Piperlongumine-Treated Human Pancreatic Cancer Cells Reveals Involvement of Oxidative Stress and Endoplasmic Reticulum Stress Pathways.

Authors:  Harsharan Dhillon; Sujan Mamidi; Phillip McClean; Katie M Reindl
Journal:  J Med Food       Date:  2016-04-27       Impact factor: 2.786

8.  Piperlongumine reverses doxorubicin resistance through the PI3K/Akt signaling pathway in K562/A02 human leukemia cells.

Authors:  Qingwei Kang; Shu Yan
Journal:  Exp Ther Med       Date:  2015-02-03       Impact factor: 2.447

9.  Piperlongumine promotes autophagy via inhibition of Akt/mTOR signalling and mediates cancer cell death.

Authors:  P Makhov; K Golovine; E Teper; A Kutikov; R Mehrazin; A Corcoran; A Tulin; R G Uzzo; V M Kolenko
Journal:  Br J Cancer       Date:  2014-01-16       Impact factor: 7.640

10.  Piperlongumine inhibits migration and proliferation of castration-resistant prostate cancer cells via triggering persistent DNA damage.

Authors:  Ding-Fang Zhang; Zhi-Chun Yang; Jian-Qiang Chen; Xiang-Xiang Jin; Yin-da Qiu; Xiao-Jing Chen; Hong-Yi Shi; Zhi-Guo Liu; Min-Shan Wang; Guang Liang; Xiao-Hui Zheng
Journal:  BMC Complement Med Ther       Date:  2021-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.